Abstract 6P
Background
Development of an immunosuppressive pre-metastatic microenvironment is a prerequisite for lung metastasis of breast cancer. However, previous mechanisms have focused on immune cells rather than vascular endothelial cells. Our previous research has shown that tumor cell-released autophagosomes (TRAPs) preferentially reaches the lung rather than breast cancer cells in the mouse model. Could the pre-arrival of TRAPs promote the immunosuppressive pre-metastatic microenvironment by acting on endothelial cells?.
Methods
TRAPs-treated ECs were subjected to transcriptome analysis. T cell function was detected by flow cytometry after co-culture of TRAP-treated ECs with T cells in vitro. We injected TRAPs into mice via the tail vein or established endogenous Becn1 knockdown 4T1 tumor cells model which reduced TRAPs release. Flow cytometry will be used to analyze Immunosuppressive function of PVECs and the late lung metastases was monitored. Antibody blocking assay and HMGB1 knockdown cell lines were used to detect key DAMP on the surface of TRAPs. Inhibitor-treated ECs and TLR4 knockout mice were used to detect corresponding functional receptors on the surface of ECs. CD/FillpinⅢ/CPZ -treated ECs to detect the movement of the cytoskeleton. Activation of signal pathways was detected by Western blot.
Results
TRAPs from breast tumor cell lines stimulated the upregulation of PD-L1 in PVECs via a HMGB1-TLR4–MyD88–p38/STAT3 signal cascade and depended on the movement of the cytoskeleton of ECs. TRAPs-treated ECs suppressed IFN-γ secretion and proliferation of CD4+ and CD8+ T cells in vitro and in vivo. Anti-PD-L1 treatment upregulated pulmonary T-cell function and reduced lung metastasis in tumor-bearing mice.
Conclusions
These findings elucidate a novel role and mechanism of TRAPs-induced immunosuppression of vascular endothelial cells in the pre-metastatic microenvironment. TRAPs or their surface HMGB1 represent important therapeutic targets to reverse immunosuppressive formation, while also providing a new theoretical basis for the treatment of early breast cancer with PD-L1 antibodies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wu, X. Zhou, C. Wu.
Funding
National Natural Science Foundation, China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract